Tag Archives: Emerging Companies

JOBS Act Deconstructed: Regulatory Relief

Capitol

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act marks a key departure from the previous one-size-fits-all regulatory approach for companies conducting a public offering.  Emerging growth companies (EGCs) are now subject Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulation D

150639480

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage.  Since the JOBS Act passed, attention has focused mostly on the law’s effects on the IPO market.  This is largely because the IPO On-Ramp was the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

JOBS Act Provides Innovators with Capital Boost

jobs-act-article

Despite all the talk of gridlock and polarization in Washington these days, successful, bipartisan pieces of legislation are not a thing of the past. One of them is the Jumpstart Our Business Startups (JOBS) Act, which makes it easier for emerging growth companies to raise capital by going public. The JOBS Act provides qualifying companies with a five year “on-ramp” period to comply with some of the regulatory requirements involved when making the transition from Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Propel Small Business Innovation through Tax Reform

Jeffery_Hatfield copy

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. Over the lifetime of my company, I have lost over $100 million. But constantly losing money in an effort to advance discoveries should not overshadow the real lifeblood of biotechnology, which is the reward of seeing patients treated, lives saved, and families healed. Some of the biggest challenges companies like mine face include high research and production costs, coupled with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,